Adapting Electrolyte Solutions (NA) are specialized oral rehydration salts (ORS) formulations designed for the management of dehydration due to acute diarrhea, with a focus on adapting to the specific needs of patients with sodium (Na) restrictions or those requiring lower sodium intake. These solutions are based on the World Health Organization (WHO) and Indian National Health Mission (NHM) guidelines but feature a reduced sodium concentration compared to standard ORS. They are critical in the Indian context for managing diarrheal diseases, especially in vulnerable populations like the elderly, hypertensive patients, or those with certain renal conditions, while maintaining efficacy in rehydration.
Adult: Initially: 50-100 mL/kg within first 4-6 hours to correct dehydration. Maintenance: 100-200 mL after each loose stool, or as needed to match losses. Typically 2-3 liters per day during active diarrhea.
Note: Dissolve the entire contents of one sachet in the specified volume (usually 1 liter) of clean, preferably cooled, boiled or filtered drinking water. Use within 24 hours if stored at 2-8°C, otherwise discard. Drink small sips frequently. Do not mix with milk, juice, or soft drinks. Do not add sugar or salt. Do not boil the solution after preparation.
Adapting Electrolyte Solutions (NA) correct and prevent dehydration by utilizing the principle of coupled sodium-glucose cotransport (SGLT1) in the intestinal mucosa. Even with a lower sodium concentration, the presence of glucose actively enhances the absorption of sodium and water. The reduced sodium load decreases the risk of hypernatremia or fluid overload in susceptible individuals. The citrate/bicarbonate component corrects metabolic acidosis often associated with diarrhea.
Pregnancy: Category A: Considered safe. Dehydration from diarrhea poses a greater risk. Standard ORS is preferred, but this formulation can be used if sodium restriction is indicated (e.g., pregnancy-induced hypertension).
Driving: No effect. May improve alertness by correcting dehydration-related lethargy.
| Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride) | Increased risk of hyperkalemia due to additive potassium load. | Major |
| ACE Inhibitors (e.g., Ramipril, Enalapril) / ARBs (e.g., Telmisartan) | Increased risk of hyperkalemia. | Moderate |
| Corticosteroids (e.g., Prednisolone) | May counteract sodium-retaining effect, but monitor for hyperglycemia. | Moderate |
| Lithium | Sodium depletion can increase lithium toxicity. This formulation's lower sodium may theoretically increase risk, but clinical significance is unclear. | Moderate |
Same composition (Adapting Electrolyte Solutions (NA)), different brands: